¶ Monika Naus
Monika Naus is a Canadian epidemiologist and public health official based in Vancouver, British Columbia. She currently serves as Medical Director of the Communicable Diseases & Immunization Service at the British Columbia Centre for Disease Control (BCCDC), and a professor in the School of Population and Public Health at the University of British Columbia (UBC).[1]
Naus is active on the Canadian Immunization Committee (CIC), Canadian Immunization Registries and Coverage Network, Automated Identification of Vaccine Products Advisory Task Group, Canadian Immunization Research Network (CIRN), the National Advisory Committee on Immunization (NACI), the Vaccine Surveillance Reference Group (VSRG) and other national and provincial committees.[2][3] She is a member of the Manufacturing Safety Alliance of British Columbia[4] and the STRIVEBC Consortium.[5]
She is a fellow of the Royal College of Physicians and Surgeons of Canada and of the American College of Preventive Medicine.
¶ History
Naus obtained her medical training at the University of Alberta and her training in public health and preventive medicine at the University of Toronto.
¶ Career
Naus served as a federal field epidemiologist with the Laboratory Centre for Disease Control prior to starting her career in public health, with a focus on communicable disease prevention and control.
She was a senior medical consultant in vaccine preventable diseases and TB control for the Ontario Ministry of Health and Long-Term Care from 1990 to 1997, then served as the provincial epidemiologist in Ontario from 1997 to 2001.
She began working at the British Columbia Centre for Disease Control (BCCDC) in July 2001.
Naus chaired the National Advisory Committee on Immunization (NACI) from 2003 to 2007 after being a member for eight years.
On August 16, 2018, a study assessing the risk of narcolepsy associated with the Pandemrix vaccine against H1N1 co-authored by Naus was published in the journal Vaccine. The study was funded by the Centers for Disease Control and Prevention and supported by Public Health Ontario and the Institute for Clinical Evaluative Sciences (ICES).[6]
Naus also co-authored a study on human papillomavirus (HPV) vaccines, published in Clinical Infectious Diseases on September 6, 2019. In-kind support was provided by Merck, while funding was provided by the Michael Smith Foundation for Health Research, the Canadian Immunization Research Network, the British Columbia Ministry of Health, Nova Scotia Department of Health and Wellness, and the Quebec Ministry of Health and Social Services.[7]
¶ COVID-19
Naus participated in the Safety Working Group of the COVID-19 Immunity Task Force's Vaccine Surveillance Reference Group (VSRG).[3:1]
On August 20, 2020, Naus presented at a workshop titled The Critical Public Health Value of Vaccines – Tackling Issues of Access and Hesitancy alongside Peter Daszak, chair of the Forum on Microbial Threats and president of EcoHealth Alliance.[8] In her presentation, Naus referenced the notion of putting vaccines in the water supply, and said, “we are learning to communicate in the right way, based not just on facts, but to appeal to feelings and emotions and to work with media.”[9][10]
Naus served on NACI as a liaison representative for the Canadian Immunization Committee (CIC) during the declared COVID-19 pandemic, where she participated in recommending the use of COVID-19 vaccine for Canadians.[2:1]
¶ Publications
- August 16, 2018: Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines – Multi-country assessment
- September 6, 2019: Immunogenicity of 2 and 3 Doses of the Quadrivalent Human Papillomavirus Vaccine up to 120 Months Postvaccination: Follow-up of a Randomized Clinical Trial
¶ External links
Monika Naus. BC Centre for Disease Control. Retrieved April 21, 2022, from http://archive.today/2022.04.21-002430/http://www.bccdc.ca/our-research/people/monika-naus ↩︎
National Advisory Committee on Immunization (NACI): Membership and representation. (2020, December 18). Government of Canada. https://web.archive.org/web/20201218222110/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/naci-membership-representation.html ↩︎ ↩︎
Vaccine surveillance Reference group (VSRG). COVID-19 Immunity Task Force. Retrieved April 28, 2021, from http://archive.today/2021.04.28-205527/https://www.covid19immunitytaskforce.ca/vaccine-surveillance-reference-group-vsrg/ ↩︎ ↩︎
Dr. Monika Naus. Manufacturing Safety Alliance of BC. Retrieved April 20, 2022, from http://archive.today/2022.04.21-045637/https://safetyalliancebc.ca/people/dr-monika-naus/ ↩︎
Consortium Members. STRIVEBC. Retrieved March 29, 2022, from http://archive.today/2022.03.29-000116/https://www.strivebc.org/consortium-members ↩︎
Weibel, D., Sturkenboom, M., Black, S., de Ridder, M., Dodd, C., Bonhoeffer, J., Vanrolleghem, A., van der Maas, N., Lammers, G. J., Overeem, S., Gentile, A., Giglio, N., Castellano, V., Kwong, J. C., Murray, B. J., Cauch-Dudek, K., Juhasz, D., Campitelli, M., Datta, A. N., & Kallweit, U. (2018). Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines – Multi-country assessment. Vaccine, 36(41), 6202–6211. https://doi.org/10.1016/j.vaccine.2018.08.008 ↩︎
Donken, R., Dobson, S. R. M., Marty, K. D., Cook, D., Sauvageau, C., Gilca, V., Dionne, M., McNeil, S., Krajden, M., Money, D., Kellner, J., Scheifele, D. W., Kollmann, T., Bettinger, J. A., Liu, S., Singer, J., Naus, M., Sadarangani, M., & Ogilvie, G. S. (2019). Immunogenicity of 2 and 3 Doses of the Quadrivalent Human Papillomavirus Vaccine up to 120 Months Postvaccination: Follow-up of a Randomized Clinical Trial. Clinical Infectious Diseases, 71(4), 1022–1029. https://doi.org/10.1093/cid/ciz887 ↩︎
The Critical Public Health Value of Vaccines - Tackling Issues of Access and Hesitancy - A Workshop. National Academies of Sciences, Engineering and Medicine. Retrieved April 21, 2022, from http://archive.today/2022.04.21-051216/https://www.nationalacademies.org/event/05-28-2020/the-critical-public-health-value-of-vaccines-tackling-issues-of-access-and-hesitancy-a-workshop%23sectionMap ↩︎
Peter Daszak [@PeterDaszak]. (2020, August 20). "..'But we are learning to communicate in the right way, based not just on facts, but to appeal to feelings and emotions and to work with media'." [Tweet]. Twitter. http://archive.today/2022.04.21-050107/https://twitter.com/peterdaszak/status/1296489820034932744 ↩︎
NASEM Health and Medicine Division. (2020, August 28). Visionary Statements on Priorities in Building Vaccine Acceptance and Uptake for the Next Generation. YouTube. https://web.archive.org/web/20220421053409/https://www.youtube.com/watch?v=TpVnU6zBdU8 ↩︎